Gambogic Acid as a Non-Competitive Inhibitor of ATP-Binding Cassette Transporter B1 Reverses the Multidrug Resistance of Human Epithelial Cancers by Promoting ATP-Binding Cassette Transporter B1 Protein Degradation

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 1, 2013, Pages 25-33

  Wang, Xu ^a,b   Deng, Rongxin ^a,b   Lu, Yan ^a,b   Xu, Qin ^a,b   Yan, Ming ^a,b   Ye, Dongxia ^a,b   Chen, Wantao ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Stomatology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOCETAXEL; DOXORUBICIN; GAMBOGIC ACID; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEASOME; PROTOPANAXADIOL; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; P-GLYCOPROTEIN; SAPOGENINS; XANTHONES;

EID: 84871163118     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00921.x     Document Type: Article

References (44)

1. Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007;110: 3517-25.
2. Chantarasriwong O, Batova A, Chavasiri W, Theodorakis EA. Chemistry and biology of the caged Garcinia xanthones. Chemistry 2010;16:9944-62.
3. Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L et al. Gambogic acid inhibits the catalytic activity of human topoisomerase II alpha by binding to its ATPase domain. Mol Cancer Ther 2007;6:2429-40.
4. Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2008;7:1639-46.
5. Zhu X, Zhang H, Lin Y, Chen P, Min J, Wang Z et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother 2009;21:666-72.
6. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008;68:1843-50.
7. Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu R et al. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J Cell Biochem 2011;112:509-19.
8. Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y et al. Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009;256:135-40.
9. He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z et al. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009;9:343.
10. Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod 2011;74:1085-92.
11. Huang H, Chen D, Li S, Li X, Liu N, Lu X et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett 2011;301:221-8.
12. Batova A, Lam T, Wascholowski V, Yu AL, Giannis A, Theodorakis EA. Synthesis and evaluation of caged Garcinia xanthones. Org Biomol Chem 2007;5:494-500.
13. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
14. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009;10:218-27.
15. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-62.
16. Gatti L, Beretta GL, Cossa G, Zunino F, Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 2009;9:1102-12.
17. Maraz A, Furak J, Palfoldi R, Eller J, Szanto E, Kahan Z et al. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res 2011;31:1431-6.
18. 2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci 2002;16:159-65.
19. Zhu GY, Li YW, Tse AK, Hau DK, Leung CH, Yu ZL et al. 20(S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells. Eur J Pharmacol 2011;668:88-98.
20. Yang Z, Wang JR, Niu T, Gao S, Yin T, Jiang ZH et al. Inhibition of P-glycoprotein Leads to Improved Oral Bioavailability of Compound K, an Anti-cancer Metabolite of Red Ginseng Extract Produced by Gut Microflora. Drug Metab Dispos 2012;40:1538-44.
21. Ye D, Zhou X, Pan H, Jiang Q, Zhong L, Chen W et al. Establishment and characterization of an HPV16 E6/E7-expressing oral squamous cell carcinoma cell line with enhanced tumorigenicity. Med Oncol 2011;28:1331-7.
22. Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 2011;117:86-95.
23. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
24. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976;59:253-76.
25. Ludwig JA, Szakacs G, Martin SE, Chu BF, Cardarelli C, Sauna ZE et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006;66:4808-15.
26. Zhao R, Liu XQ, Wu XP, Liu YF, Zhang ZY, Yang GY et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett 2010;287:150-6.
27. Nabekura T, Yamaki T, Hiroi T, Ueno K, Kitagawa S. Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol Res 2010;61:259-63.
28. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010;70:7981-91.
29. Wei Y, Wang X, Wang L. Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells. Mol Vis 2009;15:1243-51.
30. Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS ONE 2009;4:e7415.
31. Zhao LM, He XJ, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br J Clin Pharmacol 2009;68:395-401.
32. Iwaki K, Sakaeda T, Kakumoto M, Nakamura T, Komoto C, Okamura N et al. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. J Pharm Pharmacol 2006;58:1617-22.
33. Wang XK, Fu LW. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. Curr Drug Metab 2010;11:618-28.
34. Porcelli L, Lemos C, Peters GJ, Paradiso A, Azzariti A. Intracellular trafficking of MDR transporters and relevance of SNPs. Curr Top Med Chem 2009;9:197-208.
35. Dai J. Chemo-enzymatic transformation of taxanes and their reversal activity towards MDR tumor cells. Curr Top Med Chem 2009;9:1625-35.
36. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009;69:416-21.
37. Yu L, Wu WK, Li ZJ, Liu QC, Li HT, Wu YC et al. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol 2009;75:1364-73.
38. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 2006;317:850-7.
39. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007;293:C509-36.
40. Chen JQ, Contreras RG, Wang R, Fernandez SV, Shoshani L, Russo IH et al. Sodium/potassium ATPase (Na+, K + -ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs? Breast Cancer Res Treat 2006;96:1-15.
41. Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y et al. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol 2009;218:248-55.
42. Rao PS, Mallya KB, Srivenugopal KS, Balaji KC, Rao US. RNF2 interacts with the linker region of the human P-glycoprotein. Int J Oncol 2006;29:1413-9.
43. Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 2009;284:2657-71.
44. Pan W, Yu C, Hsuchou H, Kastin AJ. The role of cerebral vascular NFkappaB in LPS-induced inflammation: differential regulation of efflux transporter and transporting cytokine receptors. Cell Physiol Biochem 2010;25:623-30.